Chemotherapy-induced peripheral neuropathy in cancer patients: a four-arm randomized trial on the effectiveness of electroacupuncture by Rostock, M et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 349653, 9 pages
http://dx.doi.org/10.1155/2013/349653
Research Article
Chemotherapy-Induced Peripheral Neuropathy in
Cancer Patients: A Four-Arm Randomized Trial on
the Effectiveness of Electroacupuncture
M. Rostock,1,2,3 K. Jaroslawski,1,4 C. Guethlin,4,5 R. Ludtke,6 S. Schröder,7 and H. H. Bartsch1
1 Tumor Biology Center at the Albert Ludwigs University Freiburg, 79106 Freiburg, Germany
2 Institute of Complementary Medicine, University Hospital Zurich, 8006 Zurich, Switzerland
3Hubertus Wald Tumor Center, University Cancer Center Hamburg, 20246 Hamburg, Germany
4University Medical Center Freiburg, 79106 Freiburg, Germany
5 Institute of General Practice, Johann Wolfgang Goethe University, 60590 Frankfurt/M, Germany
6Carstens Foundation Essen, 45276 Essen, Germany
7Hanse Merkur Center for Traditional Chinese Medicine at the University Medical Center Hamburg-Eppendorf,
20246 Hamburg, Germany
Correspondence should be addressed to M. Rostock; m.rostock@uke.de
Received 8 May 2013; Accepted 7 July 2013
Academic Editor: Sookyung Lee
Copyright © 2013 M. Rostock et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Purpose. Chemotherapy-induced peripheral neuropathy (CIPN) is a common and dose-limiting side effect of cytostatic drugs.
Since there are no proven therapeutic procedures against CIPN, we were interested to define the role of electroacupuncture (EA)
from which preliminary data showed promising results. Methods. In a randomized trial with a group sequential adaptive design
in patients with CIPN, we compared EA (LV3, SP9, GB41, GB34, LI4, LI11, SI3, and HT3; 𝑛 = 14) with hydroelectric baths (HB,
𝑛 = 14), vitamin B1/B6 capsules (300/300mg daily; VitB, 𝑛 = 15), and placebo capsules (𝑛 = 17). The statistical power in this trial
was primarily calculated for proving EAonly, so results ofHB andVitB are pilot data.Results. CIPN complaints improved by 0.8±1.2
(EA), 1.7±1.7 (HB), 1.6±2.0 (VitB), and 1.3±1.3 points (placebo) on a 10-point numeric rating scale without significant difference
between treatment groups or placebo. In addition no significant differences in sensory nerve conduction studies or quality of life
(EORTC QLQ-C30) were found. Conclusions. The used EA concept, HB, and VitB were not superior to placebo. Since, contrary
to our results, studies with different acupuncture concepts showed a positive effect on CIPN, the effect of acupuncture on CIPN
remains unclear. Further randomized, placebo controlled studies seem necessary. This trial is registered with DRKS00004448.
1. Background
Chemotherapy-induced peripheral neuropathy (CIPN) is
common and can be dose limiting for several cytotoxic drugs,
for example, the antitubulins (paclitaxel, docetaxel, ixab-
epilone, and vincristine), platinum analogs (cisplatin, carbo-
platin, and oxaliplatin), and the proteasome inhibitors borte-
zomib and thalidomide. CIPN symptoms usually appear
symmetrically in a stocking-glove shaped distribution pat-
tern. Typical symptoms include numbness and tingling,
whereas neuropathic pain appears less frequently. Affected
patients experience considerable impairments including dif-
ficulty in walking, increased risk of falls, and weakness and
restrictions in fine motor skills such as writing and other dif-
ferentiatedmanual tasks. After the completion of chemother-
apy, the symptoms frequently determine the patient’s quality
of life and often considerably hinder social rehabilitation,
social reintegration, and return to work [1, 2].
Various substances including amifostine, glutathione,
vitamin E, glutamic acids, intravenous calcium and magne-
sium infusions, and neurotrophic growth factors have been
examined in clinical studies as a prophylaxis against chemo-
therapy-induced neurotoxic effects. No studies have shown
convincing evidence of substantial clinical benefit [3, 4].
Anticonvulsants (e.g., carbamazepine and in particular gaba-
pentin), tricyclic antidepressants (e.g., amitriptyline), and
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selective serotonin reuptake inhibitors (e.g., venlafaxine) play
a clinical role in the prevention and treatment of neuropathic
pain. However, these drugs are ineffective for the treatment
of the typical sensory CIPN symptoms and cannot induce
neuroprotection or neuroregeneration [5–8].
A recently published survey revealed that approximately
43% of patients with chronic peripheral neuropathy use or
have used complementary or alternative medicine (CAM),
including high doses of vitamins, magnet therapy, herbal
remedies, and chiropractic treatment. In addition, 30% of
patients used acupuncture. Approximately a quarter of the
patients stated that their symptoms improved after using
CAM therapies [9].
The WHO and leading German acupuncture societies
have long-listed neuropathy as an indication for acupuncture
[10]. Few reports have published on its effect. Several studies
demonstrated beneficial effects of acupuncture in diabetic
neuropathy [11–14], HIV-associated neuropathy [15, 16], and
in peripheral neuropathy with an unclear etiology [17]. The
very limited conclusions from these studies resulted either
from the small number of treated patients, the uncontrolled
study design, or the publications in Chinese journals with
merely an abstract in English and therefore not easy to evalu-
ate. Acupuncture in combination with electrostimulation for
treating CIPN has rarely been evaluated [18, 19]; however
it has been demonstrated to improve neuropathic pain in
paclitaxel-treated rats at both low (10Hz) and high (100Hz)
frequencies [20].
In German-speaking countries, hydroelectric baths are
traditionally used inmany rehabilitation centers for the treat-
ment of peripheral neuropathy [21]. However, their effec-
tiveness has not been proven via controlled studies. The use
of vitamin B supplements to treat neuropathy is also very
common but also without rigorous clinical evaluation [22].
In this randomized controlled trial we compared the ef-
fects of electroacupuncture with placebo, hydroelectric baths,
and vitamin B complex.
2. Methods
2.1. Study Design. The study was conducted as a randomized,
placebo-controlled trial comparing electroacupuncture (EA)
with hydroelectric baths (HB), high doses of vitamin B1 and
B6 (VitB), and a placebo for the treatment of CIPN. Patients
and physicians were blind to the VitB and placebo treatment
but not to EA or HB.
The trial was planned according to a group sequential
adaptive design with one interim analysis [23]. The experi-
mental type I error rate was set at a one-sided𝛼 = 0.025. Early
cessation was planned if either EA proved to be significantly
better than placebo (i.e., 𝑃 < 𝛼
1
= 0.0207) or showed no rel-
evant superiority (𝑃 > 𝛼
0
= 0.6).
Patients were allocated to one of the four treatment
groups by a nonstratified block randomizationwith randomly
varying block lengths. The biometrician drew numbers from
the “ranuni” random number generator of the SAS/STAT
software and prepared sealed, opaque, and sequentially num-
bered envelopes containing the treatment assignments. If
a patient fulfilled all inclusion criteria the study physician
opened the lowest numbered envelope to reveal the patient’s
assignment, that is, “EA,” “HB,” or “medical intervention.”
Patients from the latter group were given coded bottles of
study capsules that were prepared prior to the beginning of
the study by an impartial pharmacist. The bottles contained
63 capsules of VitB or placebo. Placebo and VitB capsules
were identical in form, taste, and odour. The randomization
list was kept closed by the biometrician, the pharmacist, and
the principle investigator and was not accessible to the study
physician.
The study was conducted according to the Declaration
of Helsinki and its amendments. The study protocol was
approved and accepted by the Ethics Committee of the Albert
Ludwigs-University of Freiburg.
2.2. Patients. The study enrolled male and female adult can-
cer patients, who were in remission after chemotherapy with
taxanes, platinumderivatives, or vinca alkaloids andwhopre-
sented with symptoms of CIPN. Patients were recruited from
a 3-4-week inpatient rehabilitation program in the Tumor
Biology Center at the Albert Ludwigs University Freiburg,
Germany. All patients received detailed information about
the study and provided written informed consent before
participation.
2.3. Treatments. Treatment protocols spanned 3 weeks and
were as follows.
2.3.1. Electroacupuncture (EA). 8 ± 1 sessions of EA were
scheduled to treat the affected extremities with the following
point combination: LV3 (Taichong), SP9 (Xiongxiang), GB41
(Zulingqi), GB34 (Yanglingquan) (legs; in patients withCIPN
symptoms in the lower extremities) and LI4 (Hegu), LI11
(Quchi), SI3 (Houxi), and HT3 (Shaohai) (arms; in patients
with CIPN symptoms in the upper extremities). Patients with
CIPN symptoms in the upper and lower extremities were
treated with the complete point combination. According to
the practices of traditional Chinese medicine (TCM) the
acupuncture needles were deeply inserted bilaterally until
the deqi phenomenon (sensation which spreads over the
whole body part described as “aching,” “soreness,” “pressure,”
or “tingling” [24]) was triggered. Each session included 15
minutes of electrostimulation (50Hz) consisting of a com-
bination of rectangular currents and high amplitude waves.
The stimulus strength was increased until the deqi phe-
nomenon was triggered again. The acupuncture was carried
out by two specially trained, highly experienced physicians at
the University Medical Center Freiburg who had completed
training in acupuncture with the German Physicians Associ-
ation.
2.3.2. Hydroelectric Baths (HB). 8 ± 1 sessions of HB were
scheduled to treat the affected extremities. The patients
dipped their arms up to a hand’s width above the elbow and
their feet up to a hand’s width above the ankle into a special
water basin with water at a temperature of about 35∘C. The
water served as an electrode for the skin surface. Each treat-
ment lasted for 15 minutes with cross-galvanisation of each
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individual extremity by low-frequency (50Hz) faradic cur-
rent (direct current impulses) up to the individual’s sensitive
threshold (i.e., the point where the tingling feeling is consid-
ered to be just acceptable).
2.3.3. Vitamin B Complex (VitB). The treatment consisted of
3 capsules of high-dosage vitamin B1/B6 (100mg thiamine
nitrate, 100mg pyridoxine hydrochloride) per day for three
weeks.
2.3.4. Placebo. The placebo treatment consisted of 3 lactose
capsules per day identical in form, taste, and odour to theVitB
capsules.
3. Outcomes
3.1. Primary Outcome. By means of detailed questionnaires,
patients were interviewed before the start of the therapy
(day 0), after treatment on day 21, and during follow-up on
day 84, about extension and intensity (non, mild, moderate,
or severe) of their CIPN complaints (numbness, swelling,
tingling, pain, and subjective impairment in everyday life and
at work).
Finally, patients were asked to describe how heavily they
suffered at the respective point in time from CIPN com-
plaints altogether and to rate the severity of neuropathic
symptoms on a numerical rating scale (NRS)—ranging from
0 (no complaints) to 10 (highest imaginable complaints).
The change from day 0 to day 21 on this patient-reported
numerical rating scale was the primary outcome of the study.
3.2. Secondary Outcomes. Before the start of the study (day
0) and after completion of the treatment (day 21), the
patients were examined by an independent neurologist. The
neurologist ascertained a neuropathy score and performed
electroneurographical tests.
The neuropathy score (0–15 points) was based on sensory
symptoms (0–3 points), pin sensibility (0–3 points), vibratory
threshold (0–3 points), strength (0–3 points), and deep
tendon reflexes (0–3 points). The electroneurographical tests
included sensible nerve conduction studies of the median
(upper extremities) and the sural nerve (lower extremities).
Finally, the neurologist evaluated the intensity of the
CIPN complaints by classification according to the NCI
common toxicity criteria (CTC) [25].
Examinations by the neurologist were only performed at
day 0 and day 21, while the follow-up interview after 12 weeks,
at day 84, was done in writing, via questionnaires sent to the
patients’ homes all over Germany.
Quality of life: the study participants’ quality of life was
examined at day 0, day 21, and day 84 by means of EORTC
QLQ-C30 [26].
4. Statistics
This trial was planned using a group-sequential adaptive
design which allowed for an adaptation (i.e., recalculation)
of sample sizes after the first interim analysis. A priori power
calculation showed that our test procedure had a type II error
probability to stop the trial early for nonsuperiority (i.e., 𝑃 >
𝛼
0
= 0.6) of 16.7% (type II error) if EA had a moderate effect
beyond the placebo of 0.5 standard deviations.
The data were analyzed using ANCOVA and modeling
the treatment group and the baseline value (linear predictor)
as covariates. Within this model, treatment groups were
compared in pairs by one-sided t-tests following the principle
of a priori ordered hypothesis [27]. All six comparisons
were ordered according to a previously defined list which
started with the comparison of EA and placebo. This list was
processed successively and a subsequent comparisonwas per-
formed if and only if the actual comparison could be rejected
at the nominal level (i.e., 0.0207 at the interim analysis). This
procedure ensured that the overall experimental type I error
rate was maintained.
All analyses were performed based on intention to treat;
that is, all randomized patients who received at least one
study treatment were included in all (effectiveness or safety)
analyses. Missing values were imputed using last observation
carried forward [28].
5. Results
From September 2000 to February 2003 a total of 199 cancer
patients with CIPN were assessed for eligibility and 60 were
randomized into one of the four treatment groups (Figure 1).
The main reasons for exclusion were pretreatment with
vitamin B (𝑁 = 40), progressive cancer (𝑁 = 22), ongoing
chemotherapy (𝑁 = 16), treatment with cytostatic drugs not
allowed in the protocol (𝑁 = 17), or patient’s unwillingness
to take part (𝑁 = 26). Immediately after randomization
one patient in the HB group withdrew his consent (before
receiving any study treatment). 4 patients stopped treatment:
1 EA patient stated he was anxious of being needled (day 1),
1 VitB patient’s tumor progressed (day 13), 1 placebo patient
withdrew his consent (day 1), and 1 VitB patient found the
study too much strain (day 1). Another 4 patients were lost to
follow-up after day 21 without providing any reason.
(a) Baseline Data.Themajority of patients were female (78%)
and were on average 52.7 ± 10.0 years old, and 92% had
ECOG performance status of 0. Nineteen patients were obese
(BMI > 30). Four patients (3 HB, 1 placebo) presented with
additional neurological problems other thanCIPN, 2 patients
had facial paresis, one patient had double vision, and one had
diminished strength in the right hand. Overall, the groups
were balanced with regard to demographic characteristics,
health status, and comorbidities (Table 1).
The underlying cancer diagnoses as well as the cancer
treatments were very heterogeneous within the study cohort
(Table 2). Seventeen patients had a lymphoma (4 Hodgkin
and 13 non-Hodgkin), and 42 patients had solid tumors,
predominantly breast cancer (21) and ovarian cancer (13).
Breast cancer was the most frequent disease in the placebo
group and lymphoma in the HB group. Due to these imbal-
ances there were also some differences in the use of chemo-
therapeutic drugs: vinca alkaloids were most often used in
the VitB group and taxanes in the EA and the placebo
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Assessed for eligibility    
Excluded: N = 139
Not meeting inclusion criteria: N = 106
Refused to participate: N = 26
Other reasons: N = 7
Randomized
N = 60
Lost to follow-up:
N = 1
Stopped treatment
N = 1
Lost to follow-up:
N = 0
Stopped treatment
N = 0
Lost to follow-up:
N = 2
Stopped treatment
N =2
Lost to follow-up:
N = 1
Stopped treatment
N = 1
Analysed:
N = 14
Analysed:
N = 13
Analysed:
N = 15
Analysed:
N = 17
Lost to follow-up:
N = 1
Lost to follow-up:
N = 0
Lost to follow-up:
N = 4
Lost to follow-up:
N = 3
Analysed:
N = 14
Analysed:
N = 13
Analysed:
N = 15
Analysed:
N = 17
Allocated to EA
N = 14
Received treatment
N = 14
Allocated to HB
N = 14
Received treatment
N = 13
Allocated to VitB
N = 15
Received treatment
N = 15
Allocated to placebo
N = 17
Received treatment
N = 17
Allocation
Follow-up, day 84
Follow-up, day 21
N = 199
Figure 1: Flow chart.
Table 1: Basic data (no. of patients or mean ± SD).
EA HB VitB Placebo
Sex (m : f) 4 : 10 1 : 12 5 : 10 3 : 14
Age (years) 49.9 ± 9.6 52.3 ± 11.3 56.3 ± 11.1 52.0 ± 8.1
Body mass index (kg/m2) 24.1 ± 4.1 25.8 ± 5.5 24.5 ± 3.3 26.1 ± 4.9
General condition (ECOG score 0) 14 (100%) 11 (84.6%) 14 (93.3%) 15 (88.2%)
Neurological problems (other than CIPN) 0 (0.0%) 3 (23.1%) 0 (0.0%) 1 (5.9%)
groups, but these differences were statistically not signifi-
cant (all 𝑃 values > 0.30, chi-square tests). Moreover, the
number of chemotherapy courses in total, or with neurotoxic
chemotherapy only, was comparable between the groups (𝑃 =
0.291 and 𝑃 = 0.667, Kruskal-Wallis tests).
The mean time since first cancer diagnosis ranged from
12.1 months in the EA to 24.9 months in the HB group.
As the latter was dominated by an extreme exception (112
months) these differences were not statistically relevant (𝑃 =
0.825, Kruskal-Wallis test). Similarly, mean times from the
last chemotherapy, last surgery, or last radiotherapy were
comparable between groups (all 𝑃 values >0.25).
Only a few patients (𝑁 = 7; 11.9%) reported that their
first CIPN complaints had occurred after the chemotherapy
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Table 2: History of cancer and CIPN (no. of patients or mean ± SD).
EA HB VitB Placebo
Breast cancer 6 (42.9%) 3 (23.1%) 4 (26.7%) 8 (47.1%)
Ovarian cancer 3 (21.4) 3 (23.1%) 4 (26.7%) 3 (17.6%)
Other 1 (7.1%) 2 (15.4%) 1 (6.7%) 4 (23.5%)
Lymphoma 4 (28.6%) 5 (38.5%) 6 (40.0%) 2 (11.8%)
Time from first diagnosis (months) 12.1 ± 11.6 24.9 ± 38.6 14.0 ± 13.8 14.5 ± 13.7
Secondary cancer 2 (14.3%) 3 (23.1%) 4 (26.7%) 4 (23.5%)
Chemotherapy
Vinca alkaloids 4 (28.6%) 5 (28.5%) 6 (40.0%) 3 (17.6%)
Platin derivatives alone 1 (7.1%) 2 (15.4%) 0 (0.0%) 3 (17.6%)
Taxanes alone 6 (42.9%) 3 (23.1%) 4 (26.7%) 8 (47.1%)
Platin derivatives and taxanes combined 3 (21.4%) 3 (23.1%) 5 (33.3%) 5 (29.4%)
Total no. of different cytostatics 2.1 ± 1.4 1.5 ± 0.9 1.7 ± 1.0 2.0 ± 0.8
No. of diff. neurotoxic cytostatics only 1.6 ± 1.2 1.1 ± 0.3 1.2 ± 0.4 1.3 ± 0.6
Time from last chemotherapy (weeks) 20.1 ± 27.4 27.8 ± 49.3 8.7 ± 5.8 14.2 ± 17.0
Cancer surgery 11 (78.6%) 6 (46.2%) 10 (66.7%) 15 (88.2%)
Radiotherapy 9 (64.3%) 8 (61.5%) 7 (46.7%) 13 (76.5%)
Duration of CIPN > 6 months 6 (42.9%) 5 (38.5%) 5 (33.5%) 4 (23.5%)
CIPN stable or worsened 9 (64.3%) 7 (53.8%) 9 (60.0%) 10 (58.8%)
Table 3: CIPN: detailed subjective complaints.
Symptoms EA HB VitB Placebo Sum
𝑁 = 14 (%) 𝑁 = 13 (%) 𝑁 = 15 (%) 𝑁 = 17 (%) 𝑁 = 59 (%)
Numbness 11 (78.6%) 10 (76.9%) 13 (86.7%) 16 (94.1%) 50 (84.7%)
Sensation of swelling 9 (64.3%) 10 (76.9%) 8 (53.3%) 12 (70.6%) 39 (66.1%)
Parasthesia 14 (100%) 13 (100%) 11 (73.3%) 15 (88.2%) 53 (89.8%)
Pain 7 (50%) 6 (46.2%) 6 (40%) 2 (11.8%) 21 (35.6%)
Subjective impairment in walking 7 (50%) 8 (61.6%) 9 (60.0%) 14 (82.4%) 38 (64.4%)
Subjective impairment in fine motor skills 7 (50%) 8 (61.6%) 10 (66.7%) 10 (58.9%) 35 (59.3%)
was finished; mostly, complaints were first noticed during
chemotherapy. Symptoms usually started during the first or
second chemotherapy cycle. At the start of the study, one-
third of the patients had been experiencing CIPN for more
than 6 months (𝑁 = 20; 33.9%) and another two-fifths had
it for more than 3 months (𝑁 = 25; 42.4%). In 31 patients
the CIPN had been stable over the last 4 weeks (52.5%), in
23 patients it had improved (38.9%), and in 4 patients it had
worsened (6.8%). The treatment groups were balanced with
respect to all these parameters (all 𝑃 values >0.15, Kruskal-
Wallis tests).
Although statistically not significant (𝑃 = 0.263, Kruskal-
Wallis test), mean baseline symptoms varied considerably
between groups and ranged from 4.0 ± 1.7 in the EA to 5.5 ±
2.6 in the HB group (Table 4 and Figure 2). At study entry
subjective CIPN complaints of the included patients differed
as shown in Table 3: while every patient in EA andHB groups
suffered from parasthesia, only three-quarters in vitamin B
group and 88% in placebo group did so. In the placebo group
less patients described painful neuropathy compared to the
treatment groups. Subjective impairment in fine motor skills
was nearly equal in all four groups.
(b) Treatment Results. Symptoms improved similarly in all
groups during the three weeks of treatment and remained
at this lower level for another 9 weeks, except in the HB
group where some deterioration was observed. At day 21,
improvementwas best in theHB (1.7±1.7) and theVitB group
(1.6±2.0). Compared to placebo (1.3±1.3) EA showed worse
effects (0.8 ± 1.2) resulting in a group difference of 𝑑 = −0.3
(CI: −1.4 to 0.8; 𝑃 = 0.705). As the 𝑃 value exceeded the
predefined threshold of 𝛼
0
= 0.6, the study was stopped early
at the first interim analysis. Moreover, improvements in the
EA group were smaller than in the VitB group (𝑑 = −0.5;
CI: −1.7 to 0.6) and the HB group (𝑑 = −0.2; CI: −1.3 to 0.9)
(Table 4).
The neuropathy score decreased in all groups during
treatment to a similar degree. Improvements were observed
most frequently in the EA group and were smallest in the
HB and placebo groups (Table 5). Group differences were
not significant between any two groups; for example, the
difference between EA and placebo was 𝑑 = −0.4 (CI: −1.1
to 0.3; 𝑃 = 0.128).
There were no statistically significant differences between
the treatment groups by electroneurographical test results
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Table 4: (a) CIPN perceived symptom severity (NRS) day 21–
day 0 and day 84–day 0; (b) NRS—subjective CIPN complaints
(ANCOVA day 21).
(a)
Group Day Mean ± SD
Diff. mean
day 21–day 0
day 84–day 0
EA (𝑁 = 14)
0 4.0 ± 1.7
21 3.2 ± 1.9 −0.8
84 3.4 ± 1.9 −0.6
HB (𝑁 = 13)
0 5.5 ± 2.6
21 3.8 ± 2.9 −1.7
84 4.7 ± 3.3 −0.8
VitB (𝑁 = 15)
0 4.9 ± 1.8
21 3.3 ± 2.3 −1.6
84 3.1 ± 1.6 −1.8
Placebo
(𝑁 = 17)
0 4.9 ± 2.1
21 3.6 ± 1.6 −1.3
84 3.1 ± 1.3 −1.8
(b)
Difference 95% CI One-sidedt-test
Two-sided
t-test
EA versus
placebo 0.3 −0.8–1.4 𝑃 = 0.705 𝑃 = 0.59
HB versus
placebo −0.2 −1.3–0.9 𝑃 = 0.35 𝑃 = 0.699
EA versus VitB 0.5 −0.6–1.7 𝑃 = 0.83 𝑃 = 0.34
HB versus VitB 0.0 −1.1–1.2 𝑃 = 0.52 𝑃 = 0.959
EA versus HB 0.2 −0.9–1.3 𝑃 = 0.65 𝑃 = 0.699
VitB versus
placebo −0.2 −1.3–0.8 𝑃 = 0.323 𝑃 = 0.646
(Table 6) and NCI common toxicity criteria classification
(Table 7). Sensory neuropathy symptoms improved similarly
in all four groups: 32.7% with a CTC grade 2 or 3 at day 0 and
17.3% at day 21; 0% with a CTC grade 0 at day 0 and 21.2% at
day 21.
Health related quality of life also moderately improved in
all groups, but without any statistical group differences at day
21 (Table 8).
6. Discussion
In this randomized, placebo-controlled study, electroacu-
puncture, hydroelectric baths, and a high dosage of oral vita-
min B1/B6 combination were studied to determine their
effectiveness and safety in patients with chemotherapy-
induced peripheral neuropathy. Sixty cancer patients were
included within the setting of an inpatient oncology rehabil-
itation program.
In our study we observed no therapeutic advantage of
electroacupuncture over an orally administered placebo con-
trol. In addition, no effects of hydroelectric baths and vitamin
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Figure 2: CIPN perceived symptom severity day 0, day 21, and day
84 (severity rated on a 10-point numerical rating scale (NRS); all
values are mean ± SD).
Table 5: Neuropathy score (mean ± SD).
Group Day 0 Day 21 Change day0 to 21
Neuropathy
score (0–15)
EA 4.5 ± 1.5 3.5 ± 1.2 −1.0 ± 1.1
HB 5.0 ± 2.2 4.4 ± 2.1 −0.6 ± 0.9
VitB 3.9 ± 1.2 3.2 ± 1.3 −0.7 ± 0.8
Placebo 4.1 ± 1.5 3.5 ± 1.7 −0.6 ± 1.0
B1/B6were demonstrated. It should, however, been taken into
consideration that the statistical power of the later tests was
low because the study was powered to test the effectiveness of
electroacupuncture.
When evaluating our results, several limitations must
be considered. Unexpectedly, the intensity of CIPN com-
plaints at baseline was relatively low, particularly in the elec-
troacupuncture group. Our study design, including sample
size calculations, was based on experiences with patients with
more severe CIPN symptoms and higher pain scores showing
larger clinical effects of electroacupuncture treatment. Con-
sequently, there were no large margins for many patients to
improve considerably, and our study results might have been
influenced by a floor effect.
In spite of the limitation of this study, we are convinced
that reporting negative results is of importance. Studies re-
porting positive results are more likely to be published [29],
while negative results more often have to be published in
journals with lower impact factors [30]. By publishing our
negative results, we hope our data will have an impact on
the critical discussion on study designs and acupuncture
concepts for CIPN.
In 2006, a small case series (𝑛 = 5) reported encour-
agingly positive results on acupuncture without electrical
stimulation for the treatment of CIPN [31]. All five patients
showed improvements in pain, numbness, and tingling. In
contrast to our study, all patients suffered from painful
peripheral neuropathy with high symptom scores and were
treated over a time period of 12 weeks. The authors pointed
out that they are carrying out a larger trial, the results of
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Table 6: Electroneurographical tests (amplitude and nerve conduction velocity) day 21–day 0 (mean ± SD).
Group Day Sural nerve Median nerve
Amplitude (norm > 10𝜇V) NCV (norm > 42m/s) Amplitude (norm > 7𝜇V) NCV (norm > 45m/s)
EA (𝑁 = 13) 0 5.4 ± 3.6 46.4 ± 4.7 19.0 ± 10.7 48.2 ± 4.7
21 7.4 ± 6.0 46.0 ± 3.7 16.8 ± 7.0 48.4 ± 4.4
Diff. mean day 21–day 0 +2.0 −0.4 −2.2 +0.2
HB (𝑁 = 12) 0 4.3 ± 2.2 46.2 ± 3.4 15.5 ± 7.8 40.7 ± 9.7
21 6.3 ± 2.6 46.8 ± 7.1 15.9 ± 9.8 46.3 ± 6.3
Diff. mean day 21–day 0 +2.0 +0.6 +0.4 +5.6
VitB (𝑁 = 13) 0 3.9 ± 2.7 45.0 ± 4.3 15.9 ± 9.8 46.9 ± 4.1
21 5.1 ± 3.8 45.0 ± 3.8 15.3 ± 6.4 51.2 ± 3.1
Diff. mean day 21–day 0 +1.2 ±0 −0.6 +4.3
Placebo (𝑁 = 14) 0 5.3 ± 3.1 45.3 ± 4.2 17.5 ± 9.5 47.1 ± 7.5
21 6.3 ± 3.4 45.9 ± 5.8 16.8 ± 8.5 50.6 ± 6.0
Diff. mean day 21–day 0 +1.0 +0.6 −0.7 +3.5
Table 7: NCI common toxicity criteria (sensory item) day 21–day 0.
Group Day
CTC sensory item
0 1 2 3
N (%) N (%) N (%) N (%)
EA (𝑁 = 13) 0 0 (0%) 10 (76.9%) 3 (23.1%) 0 (0%)
21 2 (15.4%) 9 (69.2%) 2 (15.4%) 0 (0%)
HB (𝑁 = 12) 0 0 (0%) 4 (33.3%) 6 (50.0%) 2 (16.7%)
21 2 (16.7%) 7 (58.3%) 2 (16.7%) 1 (8.3%)
VitB (𝑁 = 13) 0 0 (0%) 11 (84.6%) 2 (15.4%) 0 (0%)
21 3 (23.1%) 9 (69.2%) 1 (7.7%) 0 (0%)
Placebo (𝑁 = 14) 0 0 (0%) 10 (71.4%) 3 (21.4%) 1 (7.1%)
21 4 (28.6%) 7 (50.0%) 3 (21.4%) 0 (0%)
which are eagerly awaited. A randomized controlled trial on
acupuncture for the treatment of CIPN without electrical
stimulation was conducted in Beijing, China. The authors
describe significant better treatment effects in the acupunc-
ture group in relation to the control group treated with
adenosylcobalamin [32]. A recently published small pilot
study on acupuncture for the treatment of CIPN (𝑛 = 11)
reports improvements in nerve conduction studies as well as
in the subjective rating of the patients [33].
Several different acupuncture concepts have been used
in the treatment of CIPN. Different to our protocol, other
studies that reported positive effects of acupuncture treat-
ments in CIPN used local points on the extremities like EX-
LE 10 (Bafeng), EX-UE 9 (Baxie), and EX-LE 12 (Qiduan)
[31, 33–35] or ear acupuncture for neuropathic pain [36]. In
particular the local points on the affected limb/region might
activate local, segmental, and spinal and central reflexes in
accordance with results on animal models [20].
In traditional Chinese medicine an individualized
approach with personalized acupuncture treatment is usually
expected, while in acupuncture studies there is the necessity
of standardization of the procedures, as done in this study.
So our results only indicate that our particular standardized
acupuncture protocol might not be effective in the treatment
of CIPN, but the results cannot be generalized to other
acupuncture concepts.
This study was embedded in a routine care rehabilita-
tion program delivered at a specialized clinic in Southwest
Germany. Participating patients came from many regions
in Germany and thus were only available for a three-week
treatment and observation period. Considering the frequent
long-term chronic course of the CIPN symptoms it cannot
be excluded that a longer treatment period might have
yielded different results for electroacupuncture or one of the
other therapies under study. Prior studies on acupuncture
treatment in peripheral neuropathy have shown that mea-
surable results can only be found after a longer period of
treatment up to 10 weeks [17]. While peripheral neuropathy
is a disease with structural damage of the nerves, any stable
successful treatment has to induce neuroregeneration. The
time of functional recovery varies, ranging usually from 3 to
6 months, depending on the level of the lesion and factors
in regeneration [37]. So effects of treatment naturally take
longer than in other indications of acupuncture treatment
with functional states like in pain or vegetative imbalance.
All participating patients were not treated exclusively
by the therapies under study but concomitantly received
various medical and psychological interventions, depending
on the individual need of each patient. This included regu-
lar participation in sport therapy sessions, psychoeducative
groups, art therapies, ergotherapies, relaxation methods,
physiotherapies, massages, and lymph drainages. Effects of
these interventions may have contributed to a remarkable
effect in the placebo group—as well as to all other groups—
thus possibly diminishing the estimated group differences.
Positive effects of this program—as delivered in the study
center—have already been demonstrated [38].
Nevertheless further studies are necessary, to evaluate
the role of acupuncture in the treatment of CIPN. The use
of nerve conduction studies as an objective parameter for
the evaluation of treatment effects [17] as well as recently
introduced better outcome measures for the standardization
of studies of CIPN will be helpful to improve the quality of
future studies [39].
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Table 8: Quality of life (EORTC QLQ-C30) day 0–day 21–day 84.
EORTC QLQ-C30 Day EA HB VitB Placebo Sum
scale Mean SD Mean SD Mean SD Mean SD Mean SD
Physical functioning
0 72.4 22.2 61 22.4 68.4 15.8 75.3 15.6 69.7 19.4
21 84.4 13.2 66.7 24.5 75.1 12.7 87.5 10.2 79.1 17.3
84 82.3 12.2 67.3 26.5 80.5 15.7 85.6 11.2 79.5 17.9
Role functioning
0 58.3 34.4 38.5 30.7 37.8 27.8 52.9 28.4 47.2 30.8
21 72.6 26.6 61.5 37.5 58.9 20.8 74.5 23.7 67.2 27.5
84 64.5 30.3 56.4 31.6 53.3 29.7 71.4 16.2 61.9 27.4
Emotional functioning
0 63.1 21.6 44.2 25.3 54.4 27.1 62.3 26.4 56.5 25.7
21 72.6 15.1 62.2 28.0 66.7 24.6 70.4 27.3 68.2 24.1
84 70.6 18.6 52.3 35.5 62.2 32.7 72.0 19.1 64.8 27.5
Cognitive functioning
0 66.7 23.6 39.7 30.1 62.2 28.5 67.6 24.6 59.9 28.2
21 70.2 18.7 55.1 30.0 71.1 24.0 79.4 18.2 69.8 23.9
84 76.7 21.8 58.5 36.2 61.6 25.8 71.0 13.2 67.2 25.2
Social functioning
0 66.7 32.0 50.0 34.0 46.7 34.6 63.7 27.8 57.1 32.3
21 83.3 17.3 62.8 36.1 60.0 32.0 77.5 25.6 71.2 29.3
84 81.9 20.3 60.8 40.6 64.7 26.9 80.2 21.4 72.4 28.6
Global health
0 58.9 12.9 55.1 21.7 51.7 20.7 58.3 17.7 56.1 18.2
21 67.9 13.4 62.8 26.0 61.7 17.2 67.6 17.4 65.1 18.5
84 71.0 12.4 59.1 27.0 64.7 14.3 72.4 15.0 67.1 18.0
7. Conclusion
A specific standardized electroacupuncture concept, as well
as vitamin B1/B6 and hydroelectric baths, showed similar
treatment effects on CIPN and was not superior to placebo
control. While contrary to our results other studies with
different acupuncture concepts and longer treatment periods
showed a positive effect on CIPN, the effect of acupuncture
on CIPN remains unclear. Further randomized, placebo
controlled studies seem necessary.
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